NEUROCRINE BIOSCIENCES INC cotiza a 142.44 USD y tiene una capitalización bursátil de $14.5B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tab…
| Periodo | 2026-10 | 2026-07 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $2.85 | $1.94 | $1.88 |
| Estimado | $2.73 | $1.96 | $1.70 | $2.30 |
| Sorpresa | — | +45.4% | +14.1% | -18.3% |
| Métrica | NBIX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 98.2% | 57.0% | +41.1% |
| Operating Margin | 21.6% | -38.6% | +60.3% |
| Net Margin | 16.7% | -33.6% | +50.3% |
| FCF Margin | 26.2% | -13.9% | +40.0% |
| ROE | 14.7% | -40.4% | +55.1% |
| ROA | 10.3% | -32.0% | +42.3% |
| Current Ratio | 3.39 | 2.84 | +0.55 |
| Debt / Equity | — | 0.28 | — |